Skip to main content
. 2019 Jun 20;25:1076029619858409. doi: 10.1177/1076029619858409

Table 4.

Bleeding Score in the Treatment Groups.a

Bleeding Score Total
0 1 2
Imatinib 35 (74.5%), (11b) 10 (21.3%), (0b) 2 (4.3%), (1b) 47 (100%), (12b)
Dasatinib 12 (80%), (4b) 2 (13.3%), (1b) 1 (6.7%), (0b) 15 (100%), (5b)
Nilotinib 6 (100%), (1b) 0, (0b) 0, (0b) 6 (100%), (1b)

aThere was no significant difference (P = .65).

bThe patients with a secretion defect on platelet aggregometry.